Get the Latest Guidance
Health Professionals and Healthcare Workers
Virginia Department of Health’s (VDH)’s up-to-date resources are relevant to health professionals and their responses to COVID-19 in Virginia. This page includes information on vaccination, treatment, testing, and other COVID-19 topics.
Thank you for your continued work to protect the health and well-being of all Virginians.
Hot Topics for Health Professionals
FDA revises EUA for Paxlovid, Limiting Use to Pediatric Patients
On January 29, 2024, the FDA announced that emergency use authorization-labeled (EUA) Paxlovid will no longer be authorized for emergency use after March 8, 2024. However, the Paxlovid EUA will continue to authorize emergency use of Paxlovid manufactured and labeled in accordance with the NDA (NDA-labeled Paxlovid) for the treatment of mild to moderate COVID-19 in children aged 12 through 17 years.
The revised Paxlovid EUA states that Paxlovid manufactured and labeled in accordance with the EUA currently in U.S. distribution will remain authorized for use through the labeled or extended expiration date or through March 8, 2024, whichever is earlier.
Unexpired EUA-labeled Paxlovid can be dispensed to patients when consistent with the terms and conditions of the EUA. Patients who have a prescription for Paxlovid will continue to receive either EUA-labeled or NDA-labeled Paxlovid through March 8, 2024. After that date, they will receive NDA-labeled Paxlovid.
Differences in EUA and NDA labeled packaging along with answers to frequently asked questions can be found on the FDA webpage.
CMS Updates Guidance on Coverage and Claims For COVID-19 Therapeutics for with Medicare Part D Insurance
On January 5, 2024, CMS released guidance for Medicare Part D plans that describes coverage and processing claims for COVID-19 therapeutics. As a reminder, Medicare Part D plans must cover commercially available oral antivirals for COVID-19, either as a formulary product or through the formulary exception process.
CDC Issues Alert to Increase Immunization Coverage for flu, COVID-19, and RSV Immunizations and Use of Therapeutics
December 14, 2023 - CDC released a Health Alert Network (HAN) Health Advisory to alert healthcare providers to low vaccination rates against flu, COVID-19, and RSV. Low vaccination rates and ongoing increases in national and international respiratory disease activity could lead to more severe disease and increased healthcare capacity strain in the coming weeks. "Healthcare providers should administer influenza, COVID-19, and RSV immunizations now to patients, if recommended. Healthcare providers should recommend antiviral medications for influenza and COVID-19 for all eligible patients, especially patients at high-risk of progression to severe disease such as older adults and people with certain underlying medical conditions." Please see CDC's HAN Health Advisory for more information.
Expansion of the Home Test to Treat Program
December 7, 2023 - Earlier in 2023, the U.S. Government piloted the Home Test to Treat Program to provide free telehealth services for people with COVID-19 in selected U.S. cities. On December 6, 2023, the National Institutes of Health (NIH) announced the expansion of this program to include all adults nationwide and to provide services for influenza in addition to COVID-19. Through this program, adult patients can receive free at-home testing for both COVID-19 and influenza, a free telehealth visit with a medical provider, and a prescription for treatment of COVID-19 and/or influenza, if warranted. We strongly encourage you to tell eligible patients about this program and to contact the program early in the course of their illness, especially if they may need treatment. For more detailed information or to register for the program, go to the Home Test to Treat Program website.
Last Updated: February 15, 2024